Event in Progress:
Discover the latest content that has just been published on Research Tree
Genmab’s Q3 results exceeded the street’s expectations. While Darzalex remained the primary contributor, a healthy uptick was also witnessed across most of the offerings. More importantly, the lower-end of sales guidance was upgraded but profitability was narrowed due to the progress on clinical trials and planned investments. Overall Genmab’s promising virtues remain intact underpinned by its healthy pipeline, planned product launches and strong balance sheet (2023e AV credit rating of AA), whi
Companies: Genmab A/S (GMAB:CPH)Genmab A/S (GMAB:CSE)
AlphaValue
Genmab reported a good set of Q2 results. Besides Darzalex, growth was also accompanied by the healthy uptick for the other offerings. More importantly, while the sales guidance was upgraded, the profitability outlook was narrowed down due to the expansion of clinical trials and investment in future product launches. The firm’s attractiveness nonetheless remains intact and is underpinned by better product diversity and the ability to clock healthy long-term growth.
Genmab reported mixed Q1 23 results. While Darzalex remained the chief value creator, growth was also complemented by the other offerings. More importantly, despite aggressive spending plans owing to the advancement of clinical trials and investment in future product launches, the 2023 outlook was maintained. Overall our positive stance on Genmab is maintained, banking on its high-potential oncology portfolio and healthy pipeline execution ability, resulting in better product diversity.
Genmab ended 2022 on a healthy note, with sales and operating profit ahead of consensus expectations. Besides Darzalex, growth was also complemented by the healthy uptick for other offerings. While sales growth is likely to continue in 2023, the operating profitability is expected to be restrained due to the advancement of clinical trials and investments in future product launches. Nevertheless, the firm remains an attractive bet, banking on promising newer drug initiatives – also expected to re
Genmab reported better-than-expected Q3 results. Unsurprisingly, Darzalex remained the outperformer and was again one of the key reasons for another guidance upgrade. More importantly, however, healthy developments were also witnessed across the other (newer) offerings. In view of the overall recovery in the oncology markets – also acknowledged by other pharma giants in AV coverage – and its action-packed pipeline, Genmab’s attractiveness remains intact.
Genmab reported a strong set of Q2 results. While robust performances were witnessed across the offerings, unsurprisingly Darzalex remained the primary value-creator, which also led to a guidance upgrade earlier this week. Despite losing the legal battle against Janssen, the firm is progressing well w.r.t other key drugs via collaborations/partnerships with other innovators, which should gradually help reduce its dependence on Darzalex/Janssen. The ‘ADD’ recommendation is re-iterated, also consi
Genmab reported a healthy set of Q1 results. This impressive performance was witnessed across the offerings, which were again led by Darzalex. Despite maintaining aggressive spending plans, the 2022 outlook was upgraded. Meanwhile the firm has lost its legal battle with Janssen and is not opting for a review meaning that the uncertainty is over and the focus should now be shift towards the newer offerings – where good progress is being achieved. Overall, the stock looks attractive at current lev
Genmab ended 2021 on a healthy note, with sales and operating profit slightly better than street expectations. Sales growth was again driven by Darzalex, but was also well-complemented by the healthy uptick for other offerings. While 2022 is poised for further healthy sales growth, the near-term profitability is likely to be restrained by the step-up in drug development and commercialisation investments. Nevertheless, the firm remains an attractive oncology bet, set to benefit from a slew of hig
Genmab reported strong Q3 results, with both sales and operating profit exceeding street expectations. Darzalex continued its strong show along with gradual progress in other areas. As a result, management upgraded its 2021 sales growth and profitability guidance. While these promising results should result in our estimates resetting higher, the upside should be limited, given the firm’s already very pricey multiples.
Driven by the robust demand for Darzalex and higher-than-expected milestone income, Genmab reported a revenue beat in Q2. Topped with the lower-than-expected R&D and selling expenses, mainly due to timing/ phasing issues, profitability’s outperformance was also encouraging. Given the strong show, the full-year outlook has been raised. Importantly, with the recent launch of Rybrevant and the upcoming approval of tisotumab, Genmab’s recurring revenue generation capability should strengthen further
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported better-than-expected sales in Q1 21 with the ex-US region leading the momentum. Higher revenue trickled down and combined with higher financial income (driven by unrealised foreign exchange rate gains) led to a strong beat on earnings. Despite these good results, management has refrained from upgrading the guidance as there is uncertainty with respect to new cancer pa
FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex should hit the $5bn sales mark in FY21 (vs. FY20: $4.19bn). Although profitability could come under pressure, increasing R&D spend signal that the pipeline is rapidly maturing. Moreover, investments into the commercial infrastructure should make Genmab launch-ready for the next phase (two drug launches expected soon). Nonetheless, the legal battle wi
Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, particularly, Epcoritamab and DuoBody PD-L1×4-1BB, bodes well for the mid-term.
Companies: Genmab A/S
After a soft Q2 due to COVID-19, Darzalex hit the blockbuster mark in Q3 driven by the robust uptake of the subcutaneous formulation and the resulting market share gain in the frontline multiple myeloma setting. Given its convenient administration, the drug should be a key growth driver going forward. Moreover, the recently-approved Kesimpta could help Genmab make a mark in the multiple sclerosis space. More details on the R&D pipeline at the Capital Markets Day next week.
Genmab has initiated a legal fight with partner Janssen over royalty payments for multiple myeloma drug, Darzalex. There are two bones of contention – royalties for the subcutaneous formulation and the tenure of the payments. In a worst case scenario, wherein Genmab’s loses both the battles, the Danish firm’s value could reset lower by c.20%.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Genmab A/S. We currently have 24 research reports from 4 professional analysts.
Companies: Warpaint London PLC
Shore Capital
Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol
Companies: NBPE ICGT ARBB RECI CLIG HAT AVO VTA APAX
Hardman & Co
Avon Protection’s capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14–16%), concentrating on its core business of respirators and head protection. The unwinding of the armour business, alongside the consolidation of Team Wendy (acquired in H220) should enable Avon to benefit from rising global defence spending. Its strong relationship with the US DoD, and organic growth opportunities with recurring revenue from necessary product r
Companies: Avon Protection PLC
Edison
15th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio
Companies: GTC SAV FAB KRM BOOM
Hybridan
Companies: SCE HVO VLG
Cavendish
Companies: IGP RUA BOOM
17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARS TIDE SCE SNX ECK CNS TST SPEC SSTY
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 202
Companies: Tissue Regenix Group plc
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
Companies: Cambridge Nutritional Sciences PLC
Companies: BILN IGP RBN SBTX
Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli
Companies: Venture Life Group Plc
Creo Medical has released a trading update for FY23, an active year for the company, with progress made across all business segments. Traction improved in H223, following Speedboat Inject’s European clearance for upper gastrointestinal (GI) procedures and the accelerated approval and launch of Creo’s slimmest electrosurgical device, Speedboat UltraSlim. Top-line growth was supported by continued streamlining of the cost structure, resulting in a better-than-expected underlying EBITDA loss (impro
Companies: Creo Medical Group Plc
Zoetis delivered a decent set of results for the last quarter of 2022 meeting analyst expectations as well as the high end of its management guidance. Despite the economic challenges, ongoing pandemic recovery, and the political unpredictability brought on by the war in Ukraine, they delivered operational growth for the year in each of their top 13 markets. The company's unique companion animal portfolio drove its 8% operational revenue increase for the year, growing 14% operationally. In compar
Companies: Zoetis (ZTS:NYSE)Zoetis, Inc. Class A (ZTS:NYS)
Baptista Research
Share: